Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + oral etoposide as first-line therapy for extensive-stage small cell lung cancer
ChiCTR2500112982Phase 2Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and etoposide in small cell lung cancer (SCLC), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: 6-month progression-free survival rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
anlotinibetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500112982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112982.